No single treatment is ideal for Behçet's syndrome

Behçet's syndrome is a recurrent, multisystem inflammatory disorder occurring predominantly amongst populations from the Eastern Mediterranean to Asia. Autoimmune mechanisms are thought to play a key role in the development of the syndrome although its precise aetiology has yet to be defined. Treatment relies on available agents with anti-inflammatory or immunomodulatory properties (e.g. corticosteroids, colchicine, thalidomide, azathioprine, cyclophosphamide, tacrolimus, interferon-α). Choice of agent depends primarily on the specific manifestations and severity of the condition. Due to the rarity and variability of the syndrome the number of controlled clinical trials is limited and treatment is largely empirical.